CytoSorbents Corporation announced an exclusive multi-year distribution agreement with Hoang Long Pharma, a medical distributor in Vietnam specializing in the distribution of innovative pharmaceuticals, biologics, and devices to treat patients suffering from critical illnesses, immunologic disorders and deficiencies, and infections. This multi-year agreement includes all critical care applications in Vietnam, and is subject to annual minimum purchases of CytoSorb(r) to maintain exclusivity.
End-of-day quote
Other stock markets
|
||
- | - |
|
2023 | Hoang Long Group Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
2023 | Hoang Long Group Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 | CI |
1st Jan change | Capi. | |
---|---|---|
-2.36% | 8.62B | |
-1.26% | 6.95B | |
+3.39% | 2.42B | |
-0.67% | 1.73B | |
+13.66% | 1.67B | |
+11.67% | 1.57B | |
-2.38% | 919M | |
+7.51% | 936M | |
+13.06% | 618M |
- Stock Market
- Equities
- Stock
- News Hoang Long Group
- Cytosorbents Corporation and Hoang Long Group Announces Distribution Agreement